Using direct oral anticoagulants to treat cerebral venous thrombosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the safety and efficacy of direct oral anticoagulants (DOACs) in patients diagnosed with cerebral venous thrombosis (CVT). Traditionally, patients have been treated with vitamin K antagonists (VKAs), but DOACs may offer a more practical alternative with a lower risk of complications. The study will include patients who have started anticoagulant treatment within 30 days of their CVT diagnosis and will gather data on their outcomes over time. The goal is to provide additional evidence on the use of DOACs for this condition, building on previous findings from the RESPECT-CVT trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent for the use of observational data
* Age \>18 years at the time of CVT diagnosis
* Radiologically confirmed CVT diagnosis (CT-venography, MRI or catheter angiography)
* Oral anticoagulant treatment (DOAC or VKA) started within 30 days of CVT diagnosis (patient may initially be treated with heparin)
* Inclusion in the study within 90 days of CVT diagnosis

Exclusion Criteria:

* Anticoagulant treatment at the time of CVT diagnosis
* Pregnancy or lactation (post-partum women are eligible if they do not give breast-feeding)
* Mechanical heart valve
* Severe renal insufficiency (defined as an eGFR \<15 ml/min)
* Severe liver disease resulting in clinically relevant coagulopathy

Where it's running

• Jonathan Coutinho
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Jonathan Coutinho, MD, PhD — Amsterdam UMC, location AMC
• Study coordinator: Jonathan Coutinho, MD, PhD
• Email: j.coutinho@amsterdamumc.nl
• Phone: +31205669111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Danang Cerebral Venous Thrombosis Registry

  This registry collects information on adults with cerebral venous thrombosis admitted to Danang Hospital to see how the condition presents, what imaging shows, risk factors, and how patients recover.

  Recruiting Da Nang Hospital · Da Nang, Da Nang · NCT07890675

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• Anticoagulation plus batroxobin for acute cerebral venous thrombosis

  This trial tests whether adding batroxobin to standard anticoagulation helps adults with acute cerebral venous thrombosis.

  Recruiting Phase 4 Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07352358

• DOAC treatment outcomes for cerebral venous thrombosis in Vietnam

  This project will try direct oral anticoagulants (dabigatran or rivaroxaban) in adults with cerebral venous thrombosis to see if they are safe and effective in routine care.

  Recruiting Bach Mai Hospital · Hanoi, Hanoi · NCT07083609

• Evaluating the safety and effectiveness of edoxaban and rivaroxaban for treating cerebral venous thrombosis in Chinese patients

  This study is testing whether two blood thinners, edoxaban and rivaroxaban, are safe and effective for treating cerebral venous thrombosis in Chinese patients aged 18 to 80.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06947707

• Endovascular treatment plus anticoagulation for severe CVST in the MENA region

  This trial tests whether adding endovascular thrombectomy to standard anticoagulation helps adults with severe cerebral venous sinus thrombosis see better outcomes.

  Recruiting at 8 sites Middle East North Africa Stroke and Interventional Neurotherapies Organization · Alexandria and 13 other locations · NCT07548346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.